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The Journal of Immunology
Mucosal Inducible NO Synthase–Producing IgA+ Plasma
Cells in Helicobacter pylori–Infected Patients
Laura Neumann,* Mattea Mueller,* Verena Moos,* Frank Heller,† Thomas F. Meyer,‡
Christoph Loddenkemper,x Christian Bojarski,* Michael Fehlings,‡ Thomas Doerner,{
Kristina Allers,* Toni Aebischer,‖,1 Ralf Ignatius,#,1 and Thomas Schneider*,1
The mucosal immune system is relevant for homeostasis, immunity, and also pathological conditions in the gastrointestinal tract.
Inducible NO synthase (iNOS)–dependent production of NO is one of the factors linked to both antimicrobial immunity and
pathological conditions. Upregulation of iNOS has been observed in human Helicobacter pylori infection, but the cellular sources
of iNOS are ill defined. Key differences in regulation of iNOS expression impair the translation from mouse models to human
medicine. To characterize mucosal iNOS-producing leukocytes, biopsy specimens from H. pylori–infected patients, controls, and
participants of a vaccination trial were analyzed by immunohistochemistry, along with flow cytometric analyses of lymphocytes
for iNOS expression and activity. We newly identified mucosal IgA-producing plasma cells (PCs) as one major iNOS+ cell
population in H. pylori–infected patients and confirmed intracellular NO production. Because we did not detect iNOS+ PCs in
three distinct infectious diseases, this is not a general feature of mucosal PCs under conditions of infection. Furthermore, numbers
of mucosal iNOS+ PCs were elevated in individuals who had cleared experimental H. pylori infection compared with those who
had not. Thus, IgA+ PCs expressing iNOS are described for the first time, to our knowledge, in humans. iNOS+ PCs are induced in
the course of human H. pylori infection, and their abundance seems to correlate with the clinical course of the infection. The
Journal of Immunology, 2016, 197: 1801–1808.
H
elicobacter pylori is a spiral-shaped Gram-negative mi-
croaerophilic bacterium that predominantly colonizes the
antral region of the human stomach. Although H. pylori
infection often remains clinically asymptomatic, a persistent
infection-induced inflammation may result in ulceration, atro-
phy, carcinogenesis, or the development of a MALT B cell
lymphoma.
H. pylori acquisition is accompanied by the recruitment of
polymorphonuclear and mononuclear cells to the gastric mucosa
as well as the generation of specific local and systemic Ab re-
sponses (1). Infection also leads to the expression of inducible NO
synthase (iNOS or NOS2) as assessed by immunohistochemistry
and RT-PCR in gastric mucosal tissue derived from infected pa-
tients (2, 3). NO generation by iNOS represents an important
antimicrobial effector pathway (4), is a relevant signaling mole-
cule (5, 6), and has been associated with pathological conditions
(7). Expression of iNOS has been reported in gastric cancer and
MALT lymphoma (8). Although iNOS mRNA or protein has been
described in H. pylori infection, the cellular source of iNOS—and
whether NO is produced—remains unclear. This is mainly due to
significant differences between cell types and, importantly, species
in the mechanisms controlling gene expression and enzyme ac-
tivity of iNOS (9). Thus, findings obtained in murine models (10,
11) are difficult to translate to the situation in patients. To date,
iNOS expression in the gastric tissue of H. pylori–infected patients
has been attributed to polymorphonuclear neutrophils and mono-
nuclear cells (2). The present study aimed at further characterizing
these iNOS-producing mononuclear cells by means of lineage
markers in H. pylori–infected individuals, including a cohort of
volunteers who had been experimentally infected in the course of
a prior clinical H. pylori vaccination trial. By applying a combined
immunohistochemistry and flow cytometry approach, we identi-
fied human IgA+ plasma cells (PCs) as a novel major source of NO
in H. pylori–infected patients as well as in immunized or challenged
study participants. Moreover, increased numbers of iNOS+ PCs
correlated with clearance of experimental infection.
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Patients, study participants, and collection of specimens
This study and the prior vaccination trial were approved by the Human
Research Ethics committee at Charite´ Berlin (applications EA1/062/11 and
226-05a). Written consent was given by all participants. Gastric antrum
biopsy specimens were collected consecutively from 67 patients under-
going upper endoscopy (Table I). Subjects were grouped into H. pylori–
positive patients and H. pylori–negative controls according to the histo-
pathological results obtained by Warthin–Starry silver staining and the
rapid urease test on biopsy specimens. In addition, 24 antrum biopsy
specimens from participants of a prospective, randomized controlled
vaccination study (Paul Ehrlich Institute application 1097/01) conducted in
2006 at the Medical Clinic I, Charite´, Campus Benjamin Franklin, Berlin
(12), were examined by immunohistochemistry (Table I). These partici-
pants, seronegative for H. pylori and without evidence of active H. pylori
infection, had been immunized orally with live attenuated recombinant
Salmonella enterica serovar Typhi Ty21a strain containing an H. pylori
urease-expression plasmid (pUreA/B) or a plasmid expressing the H. pylori
Ag HP0231 (pHP0231). The control volunteers had been treated with Ty21a
holding the plasmid pDB2 only. The participants had been challenged with
an attenuated H. pylori strain [Baylor strain (13)] 42 d postvaccination.
Gastric antrum biopsy specimens had been collected 4 wk postvaccination
and 6 and 10 wk postchallenge. Active H. pylori infection had been diag-
nosed by the [13C] urea breath test, rapid urease test on biopsy specimens,
H. pylori detection by Warthin-Starry’s silver staining of biopsy sections, and
culture from biopsy specimens. Although the vaccines tested did not show
sufficient protection, in some participants infection was cleared before an-
tibiotic therapy was initiated 10 wk postchallenge. For the purpose of the
current study, participants were grouped into 1) those who had eradicated
H. pylori before the study endpoint (n = 7) and 2) those with persistent in-
fection throughout the study period (n = 17). Furthermore, duodenal biopsy
specimens of untreated patients infected with Tropheryma whipplei (n = 10),
HIV (n = 10), or Giardia duodenalis (also known as G. lamblia) (n = 10)
were analyzed by immunohistochemistry (Table I).
Immunohistochemistry
Biopsy specimens of 16 H. pylori–negative patients, 33 H. pylori–positive pa-
tients, and 24 study participants as well as biopsy specimens of untreated pa-
tients infected with T. whipplei (n = 10), HIV (n = 10), andG. duodenalis (n = 10)
were analyzed by immunohistochemistry. Immunohistological staining on par-
affin sections was performed for antral biopsy specimens as described previously
(14). Mouse anti–human–multiple myeloma oncogene (MUM)1 (cloneMUM1p;
Dako, Hamburg, Germany) (15), mouse anti–human-PAX5 (clone 3A7; Life-
Span BioSciences, Eching, Germany), rabbit anti–human-IgA (LifeSpan Bio-
Sciences), mouse anti–human-CD68 (Dako), and rabbit anti–human-iNOS
(Abcam, Cambridge, U.K.) were used as primary Abs. Stains were visualized
using donkey anti-mouse or donkey anti-rabbit biotin (Dianova, Hamburg,
Germany), streptavidin–alkaline phosphatase, and Fast red or EnVision (all
by Dako). Negative controls were performed by omitting the primary Ab or
the biotinylated secondary Ab, respectively. Positive cells were determined as
the mean cell counts of 3–10 high-power fields (hpf) of 0.237 mm2 each.
Preparation of lamina propria lymphocytes
Biopsy specimens of 13 H. pylori–negative controls and 13 H. pylori–
positive patients were investigated by flow cytometry. Lamina propria
lymphocytes (LPLs) were isolated from antral biopsy specimens by col-
lagenase type II (Sigma) digestion (16). Samples were incubated in 10 ml
RPMI 1640 (Life Technologies by Life Technologies) containing 7.5% FCS
(Sigma), 0.5 mg/ml collagenase type II-S (sterile filtered) (clostridiopeptidase
A derived from Clostridium histolyticum; Sigma), 0.1 mg/ml trypsin inhibitor
(from Glycine max; Sigma), and 0.1 mg/ml DNase I (Roche, Berlin,
Germany) for 15 min at 37˚C and 5% CO2, with intermittent shaking.
Tissue fragments were further disrupted using a 10-cm3 disposable sy-
ringe attached to a blunt-ended 16-gauge needle. LPLs were separated
from adjacent epithelial cells by Percoll gradient (35%/60%) centrifu-
gation (20–30 min, 2400 rpm) (GE Healthcare, Uppsala, Sweden).
Generation of B-lymphoblastoid cell lines
B-lymphoblastoid cell lines (B-LCL) were established as previously de-
scribed by transforming B cells from PBMCs with EBV released by
the marmoset lymphocyte cell line B95-8 (DSMZ ACC 100; Deutsche
Sammlung f€ur Mikroorganismen und Zellkulturen, Braunschweig, Germany)
(17). The B cell nature of the cell lines was routinely verified by flow
cytometry (FACSCalibur with the Cell Quest Pro software; BD Biosciences,
Heidelberg, Germany) upon staining for CD19–allophycocyanin (clone
HIB19; BD).
Flow cytometry
To detect surface and intracellular molecules, LPLs were incubated with
fluorochrome-labeled Abs, with or without prior fixation with parafor-
maldehyde (Sigma), and permeabilization with saponin (Sigma), according
to previously published protocols (18). The following fluorochrome-labeled
anti-human mAbs were used: anti-CD3–allophycocyanin-H7 (clone SK7;
BD), anti-CD14–allophycocyanin-H7 (clone MwP9; BD), anti-CD19–PE-Cy7
(clone SJ25C1; BD), anti-CD19–V500 (clone HIB19; BD), anti-CD19–
allophycocyanin (clone HIB19; BD), anti-CD20–Pacific Orange (clone
HI47; Invitrogen by Life Technologies), anti-CD20–PerCP (clone 2H7;
eBioscience, Frankfurt am Main, Germany), anti-CD27–PE (clone O323;
eBioscience), anti-CD38–PerCP-Cy5.5 (clone HIT2; BD), anti-CD38–
PE-Cy7 (clone HIT2; BD), anti-iNOS–Alexa Fluor 405 (clone C11; Santa
Cruz Biotechnologies, Heidelberg, Germany), anti-IgA–allophycocyanin
(clone IS11-8E10; Miltenyi Biotec, Bergisch Gladbach, Germany).
A panel of seven colors, including Abs against CD3/CD14, CD19, CD20,
CD27, CD38, iNOS, and IgA, was used to characterize PCs by high-
dimensional flow cytometry and the gating technique of fluorescence mi-
nus one controls.
For the detection of live NO-producing cells, 4-amino-5-methylamino-
29,79-difluorofluorescein diacetate (DAF-FM); Molecular Probes, Eugene,
OR) was added to the staining solution (25 mg/ml) and incubated at room
temperature for 30 min (19). The specificity of DAF-FM for NO is very
high because diaminofluorescein does not react in neutral solution with
mobile and stable oxidized forms of NO, such as NO2
2 and NO3
2, or other
reactive oxygen species, such as O2
2, H2O2, and ONOO
2. Under physi-
ological conditions, triazolofluorescein is not formed in the absence of NO
(20). After washing with PBS/0.2% BSA, DAPI (Molecular Probes) was
added immediately before flow cytometric analysis to exclude dead cells.
For the detection of intracellular cytokines, the cells were incubated for
3 h with 10 mg/ml Brefeldin A (Sigma). The following fluorochrome-
labeled anti-human mAbs were used: anti–IL-1b–FITC (AS10; BD),
anti–IL-2–PE (MQ1-17H12; BD), anti–IL-4–PE (8D4-8; BD), anti–IL-6–
FITC (MQ2-6A3; BD), anti–IL-8–FITC (AS14; BD), anti–IL-10–Alexa
Fluor 647 (JES3-9D7; eBioscience), anti–TNF-a–PE (MAb11; BD), and
anti–IFN-g–FITC (clone B27; BD).
Cells were analyzed using a FACSCanto II cytometer (BD) running with
a DivaSoft operation system (BD). Cell aggregates were excluded according
to width versus area of the forward and side scatter signal. Cytometric
fluorescence data are displayed as two-dimensional plots using log10 scales,
light scatter data on a linear scale.
Quantitative real-time PCR
Isolated LPLs and PBMCs were stained for PC and B cell surface markers.
A total of 102–104 PCs (DAPI2CD32CD142CD19+CD202CD27++CD38++)
and memory B cells (mBCs) (DAPI2CD32CD142CD19+CD20+ CD27+
CD382) were sorted on a FACSAria II cell sorter (BD Biosciences). RNA
was isolated from cells with peqGOLD RNAPure (Peqlab Biotechnologie
GmbH, Erlangen, Germany), and cDNA was prepared using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems by Life
Technologies). The expression levels of five genes were determined using
TaqMan real-time PCR after TaqMan assay–based preamplification (both
Life Technologies). Quantitative real-time PCR (qPCR) amplification was
performed using the StepOnePlus Real-Time PCR Systems (Life Tech-
nologies). The qPCR included GAPDH, as housekeeping gene; IFN-g;
TNF-a, and IL-10 as genes of interest; and IL-6, as reference gene for the
comparative Ct method.
Statistical analyses
Quantitative parameters are presented as single measurements with medians
and interquartile ranges. Data were analyzed using the nonparametric Mann–
Whitney U test (two-tailed) or the Friedman test with Dunn’s post hoc analysis
using GraphPad Prism version 5.0. The p values , 0.05 were considered
significant, as were p values , 0.017 when a Bonferroni correction was
performed.
Results
PCs constitute one third of mucosal iNOS+ cells in H. pylori–
infected patients
We investigated biopsy specimens from the stomach mucosa by
immunohistochemistry to identify the cellular sources of iNOS.
Significantly higher numbers of iNOS-expressing cells were found
in the mucosa of H. pylori–infected patients than in tissue of
uninfected controls (p = 0.0002, Fig. 1). Macrophages had been
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implicated as iNOS-expressing cells (2). Expectedly, numbers of
CD68+ macrophages were increased in patients compared with
controls (p = 0.0484, Fig. 1); however, the cells constituted only
approximately one third of iNOS-expressing cells in the gastric
mucosa of patients with H. pylori infection (Fig. 1). Morphologically,
the appearance of a sizable proportion of iNOS+ cells was similar to
that of PCs. Thus, we analyzed the histological sections for expres-
sion of the B cell lineage–specific markers, Pax5 or BSAP, specific
for B cells (21), IgA, and MUM1, which is expressed by PCs and
some germinal center B cells (15). Mucosal infiltration of Pax5+
B cells and IgA-producing PCs in patients was significantly greater
than in controls (p , 0.0001, Fig. 1). In addition, we identified
MUM1+ PCs as a major iNOS-expressing cell type (p = 0.0003,
Fig. 1) in patients. Approximately one third of the iNOS+ cells were
MUM1+ PCs, whereas this cell type was barely found in biopsy
specimens of controls (Fig. 1). To investigate if the presence of iNOS+
MUM+ PCs is a common feature of response to gastrointestinal in-
fections, we also analyzed mucosal biopsy specimens of untreated
patients with other infectious diseases of the gastrointestinal tract, that
is, of untreated patients infected with 1) Tropheryma whipplei, a
further bacterial infection; 2) HIV; or 3) Giardia duodenalis (also
known as G. lamblia), a parasitic infection associated with IgA-
mediated immunity (Table I). None of the samples from patients
with these infectious diseases showed iNOS+ MUM+ PCs in mucosal
tissues (Supplemental Fig. 1).
Early increase of mucosal iNOS-expressing PCs following
H. pylori infection in previously uninfected individuals
Antral biopsy specimens from participants of an H. pylori vaccina-
tion trial (12) provided a unique opportunity to examine the kinetics
of iNOS+ cells within the first few weeks following experimental
H. pylori infection. The numbers of iNOS+ cells, IgA+ cells, and
iNOS+MUM1+ PCs were determined using immunohistochemistry
on samples collected before infection and 6 and 10 wk postinfection
(p.i.). Before H. pylori challenge, all volunteers showed similarly low
numbers of iNOS+ and IgA+ cells as well as iNOS+MUM1+ cells
FIGURE 1. The antral mucosa of H. pylori–infected patients contains enhanced numbers of iNOS+, CD68+, PAX5+, and IgA+ cells as well as iNOS+
MUM1+ PCs. (A) Representative immunohistochemically stained paraffin sections of mucosal biopsy specimens of H. pylori–negative controls (H. pylori2)
and H. pylori–infected patients (H. pylori+). iNOS-expressing cells were identified by anti-iNOS Ab, macrophages by anti-CD68 Ab, B cells by anti-PAX5
Ab, and PCs by anti-IgA Ab. iNOS-producing PCs were visualized by double staining of anti-MUM1 and anti-iNOS Ab. Scale bar, 20 mm. (B) Quantitative
analysis of iNOS+ cells, CD68+ cells, Pax5+ cells, IgA+ cells, and iNOS+MUM1+ cells in the antral mucosa of uninfected controls (n = 16, black) and
H. pylori+ patients (n = 38, gray). Positive cells were counted per hpf and depicted as median plus interquartile ranges (Mann–Whitney test).













No. 43 24 7 17 10 10 10
Age, median (range) 56 (20–88) 52 (29–83) 29 (27–48) 30 (24–46) 57 (42–67) 51 (34–75) 48 (38–74)
Sex, no. men/no. women 15/28 7/17 7/0 17/0 9/1 7/3 8/2
Biopsy analysis
Histology 33 16 7 17 10 10 10
Flow cytometry 13 13
aIndependent of the vaccine used.
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(Fig. 2). In accordance with data from the prior trial, the vaccination
alone had no detectable effect on the gastric mucosa and did not
induce significant changes in local cytokine production (12). In
contrast, increased numbers of iNOS+ cells (14 cells per hpf), IgA+
cells (54 cells per hpf), and iNOS+MUM1+ PCs (3 cells per hpf) were
detected in the mucosa at 6 wk p.i. (p , 0.0001, Fig. 2). Cell
numbers remained increased at 10 wk p.i. (Fig. 2) and were in the
same range as in patients chronically infected with H. pylori (Fig. 1).
Importantly, vaccination did not exacerbate inflammation (12).
High infiltration of CD19+ cells, including iNOS-expressing
PCs, in the mucosa of H. pylori–infected patients
Because iNOS+ PCs had not been described before in humans, we
characterized the mucosal PCs in more detail and determined by
flow cytometry the percentages of CD19+, CD19+CD202CD27++
(PCs), CD19+CD20+CD27+ (mBCs), and CD19+CD20+CD272
(naive B cells) in the stomach mucosa of H. pylori–infected pa-
tients (Fig. 3A). Of isolated LPLs, ∼20% were CD19+ cells (Fig. 3B).
These comprised PCs (10.2% among all CD19+) and also memory
FIGURE 2. Early mucosal influx of iNOS+ cells, IgA+ cells, and iNOS+MUM1+ PCs in experimental human H. pylori infection. Quantitative analysis of
iNOS+ cells, IgA+ cells, and iNOS+MUM1+ cells in the antral mucosa of study participants (n = 24) at preinfection (pre i.) as well as 6 and 10 wk (wk) p.i.
with H. pylori. Immunohistochemical staining was performed on paraffin sections. Positive cells per hpf are depicted as associated values over time. Data
were analyzed with the Friedman test with Dunn’s post hoc analysis.
FIGURE 3. Infiltration of B cells and iNOS-expressing PCs in H. pylori+ patients. (A) Representative gating strategy for analysis of LPLs by flow
cytometry: 1) gating on lymphocytes by forward (FSC) and side scatter (SSC) properties; 2) exclusion of T cells (CD3+) and monocytes (CD14+) and gating
on CD19+ B cells; 3) detection of PCs (CD202CD27++), mBCs (CD20+CD27+), and naive B cells (CD20+CD272); 4) detection of iNOS+CD38++ PCs; and
5) detection of IgA+ PCs within iNOS+CD38++ PCs. (B) Quantitative analysis of the flow cytometric data of H. pylori–infected patients according to the
gating strategy. Values are depicted as median plus interquartile ranges (Mann–Whitney U test).
1804 iNOS+ PCs IN H. PYLORI INFECTION
 at M










and naive B cells (38.9 and 22.9% among all CD19+, respectively),
and were increased in H. pylori–infected patients compared with
uninfected controls (Fig. 3A). LPLs of control patients contained
almost no CD19+ B cells, which is in agreement with previous studies
(22). We additionally characterized by flow cytometry the PCs
(CD19+CD202CD27++) for the expression of CD38, to distinguish
them further from mBCs (CD382), and for iNOS. Notably, 50% of
the mucosal CD38++ PCs in H. pylori–infected patients expressed
iNOS and 84% of these expressed IgA (Fig. 3B).
As the presence of iNOS protein does not necessarily reflect
active enzyme (9), we investigated the functionality of iNOS en-
zyme in iNOS+ PCs. Intracellular NO production was visualized
by flow cytometry using DAF-FM-T (19). Analysis of LPLs iso-
lated from biopsy specimens obtained from infected individuals
(Fig. 4) showed consistently that ∼70% of all CD19+CD27++
CD38++CD202CD32CD142DAPI2 PCs became DAF-FM-T+
PCs; that is, these PCs expressed enzymatically active iNOS and
produced NO (Fig. 4B).
Eradication of H. pylori is accompanied by increased numbers
of mucosal iNOS+ PCs
In the prior vaccination trial (12), some individuals had cleared the
experimental H. pylori infection, whereas the majority had not,
and this correlated with H. pylori–specific T cell responses (12).
To investigate whether the course of infection may also be pos-
itively or negatively correlated with gastric iNOS+ PCs, we
quantified the numbers of iNOS+ cells, IgA+ cells, and iNOS+
MUM1+ PCs in study participants who had eradicated H. pylori
(n = 7) and individuals who had remained infected throughout the
study (n = 17). Before H. pylori challenge, both groups showed
similarly low numbers of iNOS+ and IgA+ cells as well as iNOS+
MUM1+ cells (Fig. 5). Total numbers of iNOS+ cells were in-
creased at week 6 p.i. in individuals of both groups. At 10 wk p.i.,
there was a trend toward reduced total numbers of iNOS+ cells in
both groups (Fig. 5). Numbers of IgA+ cells were also significantly
increased in both groups at 6 wk p.i. and remained high and at
comparable levels in both groups (Fig. 5). In contrast, the number
of iNOS+MUM1+ PCs—although being comparable in both
groups at 6 wk p.i. (Fig. 5)—was significantly higher at 10 wk p.i.
in those study participants who had eradicated H. pylori (Fig. 5).
iNOS-expressing B lineage cells produce pro- and anti-
inflammatory cytokines
Finally, we investigated whether the iNOS expression is associated
with B cell effector functions such as cytokine production. To
ensure sufficient cell numbers for these experiments, we used EBV-
transformed B cells as a model to study the expression of CD38
and iNOS, as well as the production of different pro- and anti-
inflammatory cytokines, including IL-1b, IL-2, IL-6, IL-8, TNF-a,
IFN-g, IL-4, and IL-10. According to previous studies, EBV trans-
formation of primary human B cells changes various cellular prop-
erties (23, 24), such as the expression of the cell activation–associated
Ag CD38 (25), and the expression of iNOS (26). Furthermore,
B-LCLs have been described as expressing various cytokines with a
high degree of heterogeneity (24, 27–32). In our B-LCL, iNOS ex-
pression was detectable in highly activated CD38++ EBV-infected
B cells, but not in CD38+ or CD382 B cells (Fig. 6A). In addition,
the highly activated B-LCL cells expressed the proinflammatory
cytokine IFN-g (Fig. 6A), but the other cytokines have not been
produced in our B-LCL (data not shown). Notably, IFN-g production
was limited to iNOS-expressing B cells (Fig. 6B).
Furthermore, we investigated the cytokine gene expression of B
lineage cells during H. pylori infection. Sorted PCs and mBCs
from isolated LPLs and PBMCs of an H. pylori–infected patient were
analyzed for relative gene expression of pro- and anti-inflammatory
cytokines by qPCR. Mucosal mBCs showed a higher expression level
FIGURE 4. Detection of NO-producing
PCs in H. pylori–infected patients. (A)
Representative gating strategy for the anal-
ysis of CD19+CD32CD142DAPI2 PCs of
H. pylori–infected patients by flow cytom-
etry: gating on PCs (CD202CD27++) within
all CD19+ B cells, and then on CD38++DAF-
FM-T+ PCs. (B) Quantitative analysis of the
data of H. pylori+ patients (n = 3). Values are
depicted as median plus interquartile ranges.
FIGURE 5. Increased numbers of iNOS+ PCs in the antral mucosa of individuals able to eradicate H. pylori. Quantitative analysis of iNOS+ cells, IgA+
cells, and iNOS+MUM1+ cells in the antral mucosa of subjects preinfection (pre i.) as well as 6 and 10 wk p.i. with H. pylori. Biopsy specimens were
obtained from study participants who had developed a persistent H. pylori infection (Persistent, n = 17, gray) and participants who had eradicated H. pylori
(Eradicated, n = 7, black). Positive cells were counted per hpf, and values are shown as the mean of cells per hpf. Values are depicted as median plus
interquartile ranges (Mann–Whitney U test followed by Bonferroni correction). The p values ,0.017 were considered significant.
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of IFN-g, TNF-a, and IL-10 mRNA than did peripheral mBCs
(Fig. 6C). In PCs, the cytokine gene expression of IFN-g, TNF-a, and
IL-10 was not detectable by qPCR. Furthermore, characterization of
isolated LPLs of an H. pylori–infected patient by flow cytometry
revealed iNOS expression by a modest proportion (2.8%) of the
mucosal mBCs (CD19+CD20+CD27+CD382) (Supplemental Fig.
2B). Intracellular cytokine staining of mucosal PCs and mBCs dem-
onstrated coexpression of IFN-g and TNF-a in iNOS-expressing
mBCs (33.1%, Fig. 6D), but not in iNOS2 mBCs, and a slightly el-
evated expression of TNF-a in the mucosal iNOS-expressing PCs
compared with the iNOS2 counterparts (15.1%, Fig. 6E).
Discussion
In the current study, we identified MUM1+ PCs as one major cell
population expressing enzymatically active iNOS in the antral
mucosa of H. pylori–infected patients. In fact, iNOS+MUM1+ PCs
FIGURE 6. iNOS-expressing B lineage cells produce pro- and
anti-inflammatory cytokines. (A) Detection of intracellular iNOS
(left) or IFN-g (right) within CD382, CD38+, and CD38++ B-LCL
cells by flow cytometry. (B) Detection of IFN-g within iNOS+
CD38++ and iNOS2CD38++ B-LCL cells. (C) Relative mRNA
expression of IFN-g, TNF-a, and IL-10 in peripheral or mucosal
mBCs during H. pylori infection. mBCs (CD19+CD20+CD27+
CD382CD32CD142DAPI2) were isolated from PBMCs or LPLs,
respectively, by FACS. The qPCR data were analyzed by the
comparative Ct method (2
2DDCt). All values are normalized to the
expression of the housekeeping gene GAPDH, and the reference
gene was IL-6. (D) Detection of intracellular TNF-a and IFN-g
within mucosal iNOS2 and iNOS+ mBCs (CD19+CD20+CD27+
CD382CD32CD142) or (E) PCs (CD19+CD202CD27++CD38++
CD32CD142) of an H. pylori–infected patient by flow cytometry.
Percentages are indicated.
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constituted approximately one third of all mucosal iNOS+ cells. In
contrast, LPLs of control patients contained no or almost no
CD19+ B cells or PCs, which is in agreement with previous studies
(22, 33). Expression of this enzyme is not a general feature of
human PCs at gastrointestinal sites because mucosal iNOS+ PCs
were not detectable in duodenal biopsy specimens of T. whipplei–,
HIV-, or G. duodenalis–infected patients, and we also detected
iNOS-negative mucosal PCs in H. pylori–infected patients.
Likewise, the analysis of transcriptome data from purified circu-
lating PCs of patients with systemic lupus erythematosus, an au-
toimmune disease marked by a distinct type 1 IFN response,
revealed no evidence of iNOS gene expression (J.R. Gruen and
T. Doerner, unpublished data). Thus, to our knowledge, this is the
first report of iNOS expression in normal, human B lineage cells,
that is, IgA+ PCs.
To date, iNOS expression in human B lineage cells has been
reported only in gastric MALT lymphoma cells (8), in B cell
chronic lymphocytic leukemia cells (34), or constitutively and at
low levels in EBV-transformed human B lymphocytes (26); the
inducing factors, however, remain unknown. In the human lung
epithelial cell line A549, functional AP-1 and NF-kB binding
elements in the promoter region were shown to confer TNF-a,
IL-1, and IFN-g cytokine inducibility (35). In this article, we
demonstrate that iNOS expression in B-LCL cells that express PC
marker proteins is linked to prominent production of IFN-g. Thus,
cytokines may regulate iNOS expression in B lineage cells in an
autocrine/paracrine fashion. Indeed, preliminary findings from
sorted memory marker–positive B cells and PCs isolated from the
gastric mucosa of an H. pylori–infected patient are in agreement
with this idea because only iNOS+ cells also showed detectable
IFN-g, TNF-a, or only TNF-a signals in cytofluorimetric analy-
ses, respectively. Although speculative, a combined local presence
of IFN-g and TNF-a may constitute the signals induced by
H. pylori that entertain iNOS expression in PCs in this infection.
Apart from the question of what exactly induces iNOS in the B
lineage cells described in this article, the question arises of what its
role may be. Expression of iNOS has been shown to inhibit ap-
optosis under certain circumstances (26, 34, 36) and could be
important in PCs for their survival, as shown recently for murine,
long-lived PCs residing in the bone marrow (10). In murine cells,
iNOS appears to be required for the responsiveness of PCs to IL-6
and is itself induced by IL-6 (10). For human PCs, IL-6 and TNF-a
are survival factors (37) and are present in H. pylori–infected gastric
mucosa (38).
The iNOS+, IgA+ PC subset within the intestinal lamina propria
has originally been described in mice upon microbial costimula-
tion (11). In mice, deletion of TNF-a and iNOS in B lineage cells
resulted in reduced IgA production. In addition, iNOS or NO has
been shown to regulate IgA class switch recombination in B cells
at the level of activation-induced cytidine deaminase gene ex-
pression, a key enzyme for Ig class switch (39, 40). In mice, loss
of iNOS+ IgA+ PCs also resulted in altered diversification of the
gut microbiota and in poor clearance of a gut-tropic pathogen,
Citrobacter rodentium (11), indicating that this PC phenotype is
linked to gut immunity. The nature of protective immunity to
H. pylori infection remains elusive. In the present analysis,
numbers of gastric iNOS+, IgA+ PCs differed significantly between
groups of human volunteers who were partaking in a vaccination
cum challenge study. These cells were more abundant in volunteers
who were clearing the challenge infection than in individuals who
remained infected. Epidemiological studies have not revealed a
correlation between IgA deficiency and H. pylori infection status,
and therefore, IgA is not considered to play a major role in H. pylori
immunity (33, 41, 42). However, these studies could not have possibly
been designed to address a role for any iNOS+, IgA+ PCs because
these were not yet known. In fact, IgA production on its own should
not reveal a role in this context. We detected similar total numbers of
antral mucosal IgA+ PCs in clearing and nonclearing vaccine study
participants.
Different effector function modules of B lineage cells are known.
Besides Ig, these include cytokines and, as suggested by our data,
may also contain an iNOS-dependent module. Arguably, the latter
would have to consider the diverse roles of the iNOS product, NO
and its derivatives. In the context of H. pylori infection, this may
include antimicrobial (4) and, potentially, tumorigenic (7, 43–47)
effects during infection. Interestingly, iNOS polymorphisms have
allegedly been implicated in disease outcome with respect to
gastric cancer (48, 49).
Defining the inducing signals and specific role or roles of iNOS+
human PCs will require many more studies. However, the present
report provides an incentive for these because the newly described
PC phenotype constitutes a prominent leukocyte type in the antral
mucosa of H. pylori–infected patients, and their density was in-
creased in individuals who eradicated an experimental infection;
they were not, however, a general phenotype of cells found in
gastrointestinal infections.
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